Glioblastoma is the most common primary malignant neoplasm of the central nervous
system in adults. Standard of care is resection followed by chemo-radiation therapy. Despite …

Simple Summary Novel therapeutic modalities using medical devices have the potential to
deliver effective treatment against the most aggressive form of primary brain tumour …

Background Progress in extending the survival of glioblastoma (GBM) patients has been
slow. A better understanding of why patient survival remains poor is critical to developing …

Background This study was designed to explore the progression patterns of IDH-wildtype
glioblastoma (GBM) at first recurrence after chemoradiotherapy. Methods Records from 247 …

Abstract Background GammaTile®(GT) is a recent US Food and Drug Administration (FDA)
cleared brachytherapy platform. Here, we report clinical outcomes for recurrent glioblastoma …

Radiation therapy (RT) is essential for the management of glioblastoma (GBM). However,
GBM frequently relapses within the irradiated margins, thus suggesting that RT might …

The mainstays of radiation therapy include external beam radiation therapy (EBRT) and
internally implanted radiation, or brachytherapy (BT), all with distinct benefits and risks in …

Background Though conformal partial-brain irradiation is the standard adjuvant treatment for
glioblastoma, there is no consensus regarding the optimal volume that needs to be …

Standard treatment for glioblastoma consists of surgical resection followed by radiation
therapy with concurrent and adjuvant chemotherapy. Conventional radiation clinical …

Abstract Development of efficient and specialized anti-cancer agent is highly desirable for
both basic and clinical research. Herein, a multifunctional organosilica nanoagent (MOCL …